London-based biotech Verdiva Bio has raised $410m in one of Europe’s largest ever Series A rounds, led by life sciences investor Forbion and US VC General Atlantic, as it looks to develop weight loss drugs for the buzzy GLP-1 market. It acquired the development and commercialisation rights of a pipeline of assets including an oral-based GLP-1 drug from Chinese biotech Sciwind Biosciences in 2024. Source: Sifted 9/1/2025